Abelcet is a drug owned by Leadiant Biosciences Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 18, 2019. Details of Abelcet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6406713 | Methods of preparing low-toxicity drug-lipid complexes |
Jun, 2019
(5 years ago) |
Expired
|
| US5616334 | Low toxicity drug-lipid systems |
Apr, 2014
(10 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Abelcet and ongoing litigations to help you estimate the early arrival of Abelcet generic.
Abelcet's Litigations
Abelcet been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 30, 2001, against patent number US6406713. The petitioner , challenged the validity of this patent, with JANOFF et al as the respondent. Click below to track the latest information on how companies are challenging Abelcet's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6406713 | March, 2001 |
Decision
(19 Dec, 2001) | JANOFF et al | |
US patents provide insights into the exclusivity only within the United States, but Abelcet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Abelcet's family patents as well as insights into ongoing legal events on those patents.
Abelcet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Abelcet's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 18, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Abelcet Generic API suppliers:
Amphotericin B is the generic name for the brand Abelcet. 7 different companies have already filed for the generic of Abelcet, with Apothecon having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Abelcet's generic
Alternative Brands for Abelcet
There are several other brand drugs using the same active ingredient (Amphotericin B) as Abelcet. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Astellas |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Amphotericin B, Abelcet's active ingredient. Check the complete list of approved generic manufacturers for Abelcet
About Abelcet
Abelcet is a drug owned by Leadiant Biosciences Inc. Abelcet uses Amphotericin B as an active ingredient. Abelcet was launched by Leadiant Biosci Inc in 1995.
Approval Date:
Abelcet was approved by FDA for market use on 20 November, 1995.
Active Ingredient:
Abelcet uses Amphotericin B as the active ingredient. Check out other Drugs and Companies using Amphotericin B ingredient
Dosage:
Abelcet is available in injectable, lipid complex form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/ML | INJECTABLE, LIPID COMPLEX | Prescription | INJECTION |